A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)

Completed · Phase 2 · Has a placebo group

Conditions studied: Cognitive Impairment Associated With Schizophrenia

In brief

The primary objective of the study is to evaluate the efficacy of BIIB104 in participants with CIAS, using the Working Memory Domain of the MATRICS Consensus Cognitive Battery (MCCB). The secondary objectives of this study are to evaluate the safety and tolerability of BIIB104 in participants with CIAS, and to evaluate the efficacy of BIIB104 in participants with CIAS on measures of cognition, functioning, and psychiatric symptomology.

Key facts

Study ID
NCT03745820
Run by
Biogen
People needed
195
Starts
2018-11-15
Expected to finish
2022-04-07
Last updated by the study team
2023-04-18

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.